Grifols S.A. ADR (GRFS) Stock Price, Quote & News

Company Profile

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testin...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 34 935 71 22 00

Fax: 34 938 00 80 00

Website: www.grifols.com

Address:

Parque Empresarial Can Sant Joan, Avinguda de la Generalitat, 152-158 Sant Cugat del Valles, Barcelona, Spain

DonCorleone77 Mar. 17 at 12:37 PM

$GRFS Grifols shares results of Chronos Platforms identifying early Parkinson's Grifols shared proof-of-concept data from its Chronos-PD program, demonstrating that biological changes in individuals with Parkinson's disease occur more than a decade before clinical diagnosis, with potential future implications for early detection and intervention. The data has been published as part of a publication in medRxiv and will be shared at the AD/PD 2026 conference in Copenhagen. Chronos-PD is a program driven by Grifols' subsidiary Alkahest designed to identify early signs of PD years before clinical diagnosis. The proof-of-concept study analyzed over 2,600 longitudinal plasma samples from PD cases and controls, and measured over 25,000 protein types using four complementary proteomics platforms. Researchers have confirmed PD biomarkers previously discovered and identified reproducible early PD biomarkers, validated across up to 5 independent cohorts. The study also uncovered novel, early biomarkers of PD. Chronos-PD shows that biological changes associated with PD can emerge up to 12 years before clinical diagnosis. Uncovered reproducible early molecular signals and distinct molecular patterns in PD, supporting future efforts in patient stratification and precision medicine research. Chronos is part of a broad Grifols program to find early disease biomarkers leveraging more than 100 million proprietary plasma samples connected to real-world data on thousands of conditions.

0 · Reply

Stock_Catcher Mar. 17 at 12:29 PM

$GRFS Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson’s Disease

0 · Reply

OfficialStocktwitsUser Mar. 10 at 6:18 PM

$GRFS RSI: 20.69, MACD: -0.1908 Vol: 0.37, MA20: 9.06, MA50: 9.15 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

notreload_ai Mar. 10 at 3:52 PM

Morgan Stanley downgraded $GRFS stock to Equal Weight with a lower €11 price target, citing slowdowns in key products like albumin in China and alpha-1. https://notreload.xyz/albumin-slowdown-in-china-forces-grifols-downgrade/

0 · Reply

OfficialStocktwitsUser Mar. 3 at 6:26 PM

$GRFS RSI: 37.14, MACD: -0.0701 Vol: 0.25, MA20: 9.27, MA50: 9.20 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BillionerOfKing Feb. 27 at 7:46 PM

$GRFS Current Stock Price: $8.97 Contracts to trade: $9.0 GRFS Mar 20 2026 Call Entry: $0.43 Exit: $0.73 ROI: 69% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Rickycello Feb. 25 at 12:17 PM

$GRFS bear: 6.3€ base: 15.19€ bull: 21.2€ Intrinsic value: 23.88€ Sell price target: 14.61€ (24% margin) Reward / risk: -0.88 Risk / reward: -1.13

0 · Reply

NorthStarStats Feb. 19 at 2:18 AM

For anyone following along, I developed a Python-based statistical scanner to identify stocks with near-term institutional accumulation and upward price momentum. The market perked up a bit, but still very dangerous for the momentum trader. Stock picks from the scanner: $GPN Score 98.00, $PLRX Score 98.00, $AWK Score 95.00, $APA Score 71.00, $GRFS Score 70.00

0 · Reply

WoodnighthawkFund Feb. 18 at 4:19 PM

$GRFS Grifols operates plasma-derived therapies with global demand. Debt reduction and margin recovery are key catalysts. Pricing and regulatory factors affect outlook.

0 · Reply

SuperGreenToday Feb. 9 at 9:36 PM

$GRFS Share Price: $9.56 Contract Selected: Aug 21, 2026 $10 Calls Buy Zone: $0.04 – $0.05 Target Zone: $0.08 – $0.10 Potential Upside: 76% ROI Time to Expiration: 192 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Grifols (GRFS) Reveals Advancements in Early Parkinson's Detection

Mar 17, 2026, 8:28 AM EDT - 4 days ago

Market Cap	5.41B
Revenue (ttm)	8.51B
Net Income (ttm)	565.70M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	6.56
Profit Margin	6.65%
Debt to Equity Ratio	1.27

Volume	1,560,200
Avg Vol	649,824
Day's Range	N/A - N/A
Shares Out	687.56M
Stochastic %K	7%
Beta	0.67
Analysts	Sell
Price Target	$11.10